Gilead Sciences Widens 2026 Non-GAAP Loss Forecast Despite Q3 Earnings Beat
Gilead Sciences (GILD) reported third-quarter financial results that exceeded analyst expectations on both top and bottom lines. However, the biopharmaceutical company issued a cautious outlook for the long term, widening its projected non-GAAP loss for 2026. The updated 2026 guidance now anticipates non-GAAP diluted earnings per share (EPS) between -$1.20 and -$0.85, a significant downward revision from the previous August projection of -$0.65 to -$0.30. This discrepancy between current quarterly performance and future loss forecasts suggests increased anticipated costs or structural shifts in the company's long-term financial outlook.
Tickers: $GILD
Topics: earnings_report financial_guidance non-gaap_loss
Read the full article at Seeking Alpha
Part of the story Manulife Reports Record Core Earnings and Strong Asian Growth in Q3 2026 (106 articles)